BiotechTube

LY3650150 + Placebo + Standard therapy for INCS

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Conditions

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Trial Timeline

Apr 29, 2024 → Mar 1, 2028

NCT ID
NCT06338995

About LY3650150 + Placebo + Standard therapy for INCS

LY3650150 + Placebo + Standard therapy for INCS is a phase 3 stage product being developed by Eli Lilly for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06338995. Target conditions include Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06338995Phase 3Recruiting
NCT06339008Phase 3Recruiting

Competing Products

20 competing products in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25